Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Eur J Clin Microbiol Infect Dis ; 38(5): 883-890, 2019 May.
Article in English | MEDLINE | ID: mdl-30701339

ABSTRACT

Sampling the blood compartment by an invasive procedure such as phlebotomy is the most common approach used for diagnostic purposes. However, phlebotomy has several drawbacks including pain, vasovagal reactions, and anxiety. Therefore, alternative approaches should be tested to minimize patient's discomfort. Saliva is a reasonable compartment; when obtained, it generates little or no anxiety. We setup a multiplexed serology assay for detection of Toxoplasma gondii IgG and IgM, rubella IgG, and CMV IgG, in serum, whole blood, and saliva using novel plasmonic gold (pGOLD) chips. pGOLD test results in serum, whole blood, and saliva were compared with commercial kits test results in serum. One hundred twenty serum/saliva sets (Lyon) and 28 serum/whole blood/saliva sets (Nice) from France were tested. In serum and whole blood, sensitivity and specificity of multiplex T. gondii, CMV, and rubella IgG were 100% in pGOLD when compared to commercial test results in serum. In saliva, sensitivity and specificity for T. gondii and rubella IgG were 100%, and for CMV IgG, sensitivity and specificity were 92.9% and 100%, respectively, when compared to commercial test results in serum. We were also able to detect T. gondii IgM in saliva with sensitivity and specificity of 100% and 95.4%, respectively, when compared to serum test results. Serological testing by multiplex pGOLD assay for T. gondii, rubella, and CMV in saliva is reliable and likely to be more acceptable for systematic screening of pregnant women, newborn, and immunocompromised patients.


Subject(s)
Cytomegalovirus Infections/diagnosis , Gold/chemistry , Protein Array Analysis/standards , Rubella/diagnosis , Saliva/immunology , Serologic Tests/standards , Toxoplasmosis/diagnosis , Adolescent , Adult , Antibodies, Protozoan/analysis , Antibodies, Viral/analysis , Antigens, Protozoan/chemistry , Antigens, Viral/chemistry , Child , Child, Preschool , Cytomegalovirus/immunology , Cytomegalovirus/isolation & purification , Humans , Immunoglobulin G/analysis , Immunoglobulin M/analysis , Infant , Infant, Newborn , Middle Aged , Rubella virus/immunology , Rubella virus/isolation & purification , Sensitivity and Specificity , Toxoplasma/immunology , Toxoplasma/isolation & purification , Young Adult
2.
Emerg Microbes Infect ; 7(1): 165, 2018 Sep 27.
Article in English | MEDLINE | ID: mdl-30262847

ABSTRACT

Globally, congenital toxoplasmosis remains a significant cause of morbidity and mortality, and outbreaks of infection with T. gondii represent a significant, emerging public health burden, especially in the developing world. This parasite is a threat to public health. Disease often is not recognized and is inadequately managed. Herein, we analyze the status of congenital toxoplasmosis in Morocco, Colombia, the United States, and France. We identify the unique challenges faced by each nation in the implementation of optimal approaches to congenital toxoplasmosis as a public health problem. We suggest that developed and developing countries use a multipronged approach, modeling their public health management protocols after those in France. We conclude that education, screening, appropriate treatment, and the development of novel modalities will be required to intervene successfully in caring for individuals with this infection. Gestational screening has been demonstrated to be cost-effective, morbidity-sparing, and life-saving. Recognition of the value and promise of public health interventions to prevent human suffering from this emerging infection will facilitate better patient and societal outcomes.


Subject(s)
Toxoplasma/physiology , Toxoplasmosis, Congenital/parasitology , Colombia , France , Humans , Morocco , Public Health , Toxoplasma/genetics , Toxoplasma/isolation & purification , Toxoplasmosis, Congenital/drug therapy , United States
4.
PLoS Negl Trop Dis ; 11(6): e0005670, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28650970

ABSTRACT

BACKGROUND: Congenital toxoplasmosis is a serious but preventable and treatable disease. Gestational screening facilitates early detection and treatment of primary acquisition. Thus, fetal infection can be promptly diagnosed and treated and outcomes can be improved. METHODS: We tested 180 sera with the Toxoplasma ICT IgG-IgM point-of-care (POC) test. Sera were from 116 chronically infected persons (48 serotype II; 14 serotype I-III; 25 serotype I-IIIa; 28 serotype Atypical, haplogroup 12; 1 not typed). These represent strains of parasites infecting mothers of congenitally infected children in the U.S. 51 seronegative samples and 13 samples from recently infected persons known to be IgG/IgM positive within the prior 2.7 months also were tested. Interpretation was confirmed by two blinded observers. A comparison of costs for POC vs. commercial laboratory testing methods was performed. RESULTS: We found that this new Toxoplasma ICT IgG-IgM POC test was highly sensitive (100%) and specific (100%) for distinguishing IgG/IgM-positive from negative sera. Use of such reliable POC tests can be cost-saving and benefit patients. CONCLUSIONS: Our work demonstrates that the Toxoplasma ICT IgG-IgM test can function reliably as a point-of-care test to diagnose Toxoplasma gondii infection in the U.S. This provides an opportunity to improve maternal-fetal care by using approaches, diagnostic tools, and medicines already available. This infection has serious, lifelong consequences for infected persons and their families. From the present study, it appears a simple, low-cost POC test is now available to help prevent morbidity/disability, decrease cost, and make gestational screening feasible. It also offers new options for improved prenatal care in low- and middle-income countries.


Subject(s)
Antibodies, Protozoan/blood , Immunoassay/methods , Immunoglobulin G/blood , Immunoglobulin M/blood , Point-of-Care Testing/economics , Toxoplasma/immunology , Toxoplasmosis/diagnosis , Costs and Cost Analysis , Developing Countries , Diagnostic Tests, Routine/economics , Diagnostic Tests, Routine/methods , Humans , Immunoassay/economics , Sensitivity and Specificity , United States
5.
Diagn Microbiol Infect Dis ; 86(2): 148-52, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27450223

ABSTRACT

When acquired during pregnancy toxoplasmosis can have devastating consequences on the fetus. As maternal infection is in the majority of cases subclinical, the diagnosis of toxoplasmosis relies on serological tests for the detection of IgG, IGM and the mesure of IgG avidity. We evaluated the performance of IDS-iSYS a new automatized instrument based on chemiluminescence for the diagnosis of the disease. Our study was based on non-selected samples received in our laboratory either for the determination of serological status or for distinguishing acute from chronic infection. Seven hundred eighty three samples were enrolled in the study. Compared with Architect IgG and IgM assays, the sensitivity and specificity were respectively 99% and 99% for IgG, and 75% and 97% for IgM. We observed higher remaining titers for IDS iSYS IgG, which could reduce the proportions of patients who have to be retested because of doubtful titers. IgM detection and avidity scored equivalent performance with both methods. This automate appears to be a reliable and easy-to-use tool for diagnosing toxoplasmosis in different clinical settings.


Subject(s)
Antibodies, Protozoan/blood , Antibody Affinity , Immunoglobulin G/blood , Immunoglobulin M/blood , Serologic Tests/methods , Toxoplasmosis/diagnosis , Automation, Laboratory/methods , Female , Humans , Infant, Newborn , Luminescent Measurements , Pregnancy , Prospective Studies , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...